# MannKind Corporation (MNKD)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $1.14B  
**Price:** $3.74 (+3.03%)

> MannKind Corporation is a biopharmaceutical company focused on developing and commercializing innovative inhaled therapies and devices for patients with cardiometabolic and orphan lung diseases, including diabetes, pulmonary hypertension, and fluid overload in heart and chronic kidney disease. Its key products include Afrezza, an inhaled insulin for diabetes management; FUROSCIX, a subcutaneous furosemide delivery system for edema associated with chronic heart failure or kidney disease; and Tyvaso DPI, a dry powder inhaler for pulmonary hypertension manufactured in partnership with United Therapeutics. The company also offers V-Go, an insulin delivery device. MannKind advances a pipeline of dry powder inhalation technologies, such as MNKD-201, a nintedanib formulation for idiopathic pulmonary fibrosis, alongside programs targeting nontuberculous mycobacterial lung disease and other respiratory conditions. Through strategic acquisitions like scPharmaceuticals, MannKind has expanded its cardiometabolic portfolio, emphasizing patient-centric solutions that integrate into daily life. Founded in 1991 and headquartered in Danbury, Connecticut, MannKind Corporation plays a vital role in addressing unmet needs in endocrine and rare pulmonary disorders with its proprietary Technosphere platform.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $349M | $261M | $47M | $6M | $0.02 |
| 2024 | $286M | $209M | $69M | $28M | $0.10 |
| 2023 | $199M | $136M | $11M | -$12M | $-0.04 |
| 2022 | $100M | $42M | -$69M | -$87M | $-0.34 |
| 2021 | $75M | $37M | -$53M | -$81M | $-0.32 |
| 2020 | $65M | $41M | -$25M | -$57M | $-0.26 |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $792M | $843M | -$51M | $75M | $329M |
| 2024 | $394M | $473M | -$79M | $46M | $48M |
| 2023 | $475M | $721M | -$246M | $238M | $253M |
| 2022 | $295M | $546M | -$251M | $70M | $279M |
| 2021 | $321M | $531M | -$209M | $124M | $282M |
| 2020 | $109M | $289M | -$180M | $67M | $119M |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $8M | -$5M | $14M |
| 2024 | $34M | -$10M | $33M |
| 2023 | $31M | -$42M | -$8M |
| 2022 | -$63M | -$8M | -$88M |
| 2021 | -$78M | -$11M | -$73M |
| 2020 | -$42M | -$801,000 | -$33M |

Source: [CompaniesByCap](https://companiesbycap.com/company/MNKD)